Product Description
Icosapent ethyl is a stable, highly purified ethyl ester of eicosapentaenoic acid that safely and effectively reduces cardiovascular events in the contemporary setting. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34253137/)
Mechanisms of Action: PLA2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Japan | Korea | Malaysia | New Zealand | Norway | Philippines | Romania | Saudi Arabia | Spain | Sweden | Taiwan | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Hypertriglyceridemia
Known Adverse Events: Arthralgia
Company: Mochida Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Italy, Japan, United Kingdom
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Adenoma|Adenomatous Polyposis Coli|Colorectal Cancer|Familial Adenomatous Polyposis|Hypertriglyceridemia|Influenza, Human|Liver Cancer|Nasopharyngeal Cancer
Phase 2: Communicable Diseases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EMT2 | P3 |
Active, not recruiting |
Colorectal Cancer|Liver Cancer |
2025-11-30 |
|
| EPA-POL-04 | P3 |
Active, not recruiting |
Nasopharyngeal Cancer|Familial Adenomatous Polyposis|Adenomatous Polyposis Coli|Colorectal Cancer |
2024-06-30 |
50% |
| MND2112H33 | P3 |
Completed |
Hypertriglyceridemia |
2023-07-20 |
|
| jRCT2031210362 | P1 |
Completed |
Healthy Volunteers |
2022-02-28 |